COVID-19 and Liver Disease: An Evolving Landscape DOI
Kai Zhu,

Olivia Tsai,

Daljeet Chahal

et al.

Seminars in Liver Disease, Journal Year: 2023, Volume and Issue: 43(03), P. 351 - 366

Published: Aug. 1, 2023

The COVID-19 pandemic has resulted in significant worldwide morbidity and mortality. In this review, we examine the intricate relationships between liver diseases. While respiratory manifestations of are well known, its impact consequences patients with diseases remain an area ongoing investigation. can induce injury through various mechanisms is associated higher mortality individuals preexisting chronic disease. Mortality increases severity disease level care required. outcomes autoimmune hepatitis unclear, whereas transplant recipients more likely to experience symptomatic but have comparable general population. Despite suboptimal immunological response, vaccinations safe effective disease, although cases hepatitis-like syndrome been reported. conclusion, implications diseases; early recognition treatments important for improving patient outcomes.

Language: Английский

Mortality from chronic liver disease: Recent trends and impact of the COVID-19 pandemic DOI Creative Commons
Ugo Fedeli, Claudio Barbiellini Amidei,

Veronica Casotto

et al.

World Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 29(26), P. 4166 - 4173

Published: July 6, 2023

Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms. Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of COVID-19, with severe consequences reported in elderly patients. Furthermore, impact COVID-19 on patients pre-existing digestive diseases still needs to be fully elucidated, particularly older population. This review aimed investigate GI tract, liver, and pancreas individuals without previous diseases, a particular focus elderly, highlighting distinctive characteristics observed this Finally, effectiveness adverse events anti-COVID-19 vaccination disorders peculiarities found discussed.

Language: Английский

Citations

10
Vaccine Responses in Patients with Liver Cirrhosis: From the Immune System to the Gut Microbiota DOI Creative Commons
Carlo Airola, Silvia Andaloro, Antonio Gasbarrini

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(4), P. 349 - 349

Published: March 23, 2024

Vaccines prevent a significant number of deaths annually. However, certain populations do not respond adequately to vaccination due impaired immune systems. Cirrhosis, condition marked by profound disruption immunity, impairs the normal immunization process. Critical vaccines for cirrhotic patients, such as hepatitis A virus (HAV), B (HBV), influenza, pneumococcal, and coronavirus disease 19 (COVID-19), often elicit suboptimal responses in these individuals. The humoral response, essential immunization, is less effective cirrhosis decline memory cells an increase plasma blasts, which interfere with creation long-lasting response antigen vaccination. Additionally, some T cell subtypes exhibit reduced activation cirrhosis. Nonetheless, persistence activity, while preventing infections, may help attenuate severity diseases patients. Alongside that, impairment innate particularly dendritic (DCs), prevents priming adaptive interrupting process at its onset. Furthermore, disrupts gut–liver axis balance, causing dysbiosis, production short-chain fatty acids (SCFAs), increased intestinal permeability, bacterial translocation. Undermining physiological activity system, alterations could impact vaccine response. Enhancing understanding molecular cellular factors contributing patients crucial improving efficacy this population developing better prevention strategies.

Language: Английский

Citations

3
The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis DOI Open Access
Zheng Li, Yue Hu, Bingwen Zou

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(4), P. e157 - e162

Published: July 1, 2023

Language: Английский

Citations

5
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis DOI Creative Commons

Lichen Ouyang,

Gang Lei,

Yeli Gong

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: March 11, 2024

The immunogenicity of COVID-19 vaccines in patients with liver cirrhosis remains largely unknown. purpose this meta-analysis was to investigate the and compare humoral cellular immune responses following complete vaccination between healthy controls. A systematic literature search conducted PubMed, EMBASE, Web Science from 1 January 2020 22 August 2023. Sixteen studies 2127 were included. pooled seroconversion rate 92.4% (95% CI, 86.2%–96%, I2 = 90%) significant between-study heterogeneity. Moreover, elicited a higher response compensated as compared decompensated (RR 1.069, 95% 1.011–1.131, 17%, p .019). Additionally, 10 included for comparison analysis results showed that slightly lower controls 0.972, 0.955–0.989, 66%, .001). Meanwhile, RR vs. 0.678 0.563–0.817, 0, < .0001). Our demonstrated diminished cirrhosis. Patients particularly who have completed full-doses should receive continuous attention preemptive measures.

Language: Английский

Citations

1
Serological responses to COVID-19 vaccination in patients with chronic liver diseases DOI Creative Commons
Yu‐Shan Huang, Szu‐Min Hsieh, Feng‐Chiao Tsai

et al.

Journal of the Formosan Medical Association, Journal Year: 2024, Volume and Issue: 123(11), P. 1194 - 1197

Published: June 21, 2024

Longitudinal analysis of antibody responses following three-dose COVID-19 vaccination in patients with chronic liver disease (CLD) has been limited. From August 2021 to February 2023, sequential anti-SARS-CoV-2 spike IgG titers were determined 45 CLD who received two or three doses vaccine. The geometric mean anti-spike at four weeks after the second and third 1313.16 BAU/mL 3042.29 BAU/mL, respectively, it decreased significantly from 24 (1313.16 vs. 198.42 p = 0.002) (3042.29 636.71 < 0.001) dose. participants receiving prime-boost homologous mRNA vaccines (BNT162b2 mRNA-1273) comparable between those without significant fibrosis each follow-up time point. This study demonstrated a notable decrease completion schedule CLD, highlighting importance additional booster doses.

Language: Английский

Citations

1
Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients DOI Creative Commons

Jin Cui,

Lianbang Wang, Armin Ghavamian

et al.

BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Sept. 30, 2024

Language: Английский

Citations

1
How does geographical diversity shape vaccine efficacy? DOI Creative Commons
Mohammad Abavisani, Bahareh Ansari, Negar Ebadpour

et al.

Clinical and Experimental Vaccine Research, Journal Year: 2024, Volume and Issue: 13(4), P. 271 - 271

Published: Jan. 1, 2024

Vaccination is a cornerstone of public health, saving millions lives each year by preventing variety infectious diseases. Yet, despite global vaccination efforts, emerging research highlights significant geographical disparities in vaccine efficacy and immunogenicity. These variations underscore the critical interplay between immunological factors environmental, genetic, nutritional elements across different populations. Our review article aimed to explore multifactorial reasons behind efficacy. Also, this study has shown how important host like age, obesity, gender, genetic diversity, especially within major histocompatibility complex, are determining well works. Nutritional status, namely deficiencies micronutrients such as vitamins zinc, lifestyle including stress, sleep, alcohol consumption, physical activity also have profound effects on vaccine-induced immunity. Importantly, our paper brought light influence microbial ecological factors, gut microbiome environmental pollutants, immune system's response vaccination. The findings emphasize importance tailoring strategies accommodate unique landscapes shaped societal factors. This tailored approach could enhance efficacy, reduce response, ultimately contribute fight against

Language: Английский

Citations

1
Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study DOI Creative Commons
Pimsiri Sripongpun, Nawamin Pinpathomrat,

Ratchanon Sophonmanee

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(9), P. 1455 - 1455

Published: Sept. 4, 2023

This study aimed to evaluate the antibody and cellular responses different coronavirus 2019 (COVID-19) vaccination regimens in patients with cirrhosis assess response after a vaccine booster. We conducted prospective observational of 89 41 healthy volunteers who received two COVID-19 doses. Next, we prospectively evaluated 24 booster dose. In both studies, blood samples were collected before 4 weeks vaccination, anti-spike receptor-binding domain protein IgG levels, T-cell phenotypes, effector functions assessed. The heterologous regimen (CoronaVac [SV]/AstraZeneca [AZ]) produced better CD4+IFNg+ T cell compared homogeneous regimens. second dose was similar volunteers. Patients mRNA had significantly increased titers those AZ vaccine. cirrhosis, SV/AZ resulted immune than AZ/AZ SV/SV Moreover, led greater increase

Language: Английский

Citations

3
Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases DOI Open Access
Zhiwei Chen,

Yuting Wang,

Taiyu He

et al.

Journal of Clinical and Translational Hepatology, Journal Year: 2023, Volume and Issue: 000(000), P. 000 - 000

Published: Sept. 6, 2023

Background and AimsSARS-CoV-2 vaccines-associated autoimmune liver diseases have been reported in several case reports. However, the safety immunogenicity after primary booster inactivated SARS-CoV-2 vaccination patients with (AILD) is still unknown.

Language: Английский

Citations

1
COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses DOI Creative Commons

Inês Canha,

Mário Jorge Silva,

Maria Azevedo Silva

et al.

GE Portuguese Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 31(5), P. 325 - 337

Published: Nov. 15, 2023

Three years after the beginning of SARS-CoV-2 pandemic, safety and efficacy COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study safety, immunological, clinical responses LC vaccination.

Language: Английский

Citations

1